Oslo, Norway, May 10, 2021 – Lytix Biopharma AS, a Norwegian clinical-stage immunoncology therapeutic company developing oncolytic molecule therapies to treat cancer, today announces that promising full data results from a phase I study of its lead candidate LTX-315 were published in Clinical Cancer Research, a peer-reviewed journal of the American Association for Cancer Research.
11 May, 2021
LONDON - Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, announces that hVIVO, a subsidiary of Open Orphan plc, has signed a contract with Imperial College London, as part of a Wellcome Trust funded initiative to manufacture a SARS-CoV-2 challenge virus.
11 May, 2021